Navigation Links
Report reveals why personalizing support for women with breast cancer could save lives
Date:11/22/2013

SUMMIT, N.J., Nov. 22, 2013 /PRNewswire/ -- Personalizing support for women living with breast cancer could help them achieve better health outcomes through improved adherence, according to a new White Paper published by Atlantis Healthcare.    

(Logo: http://photos.prnewswire.com/prnh/20130627/MM38791)

This latest report from the Adherence Research Summarized™ series has been published to help healthcare providers, organized customers and pharma work with patients to overcome the challenges they face while taking preventative breast cancer therapies.

The issue of non-adherence in breast cancer was recently highlighted by a study from the University of Glasgow showing that improved adherence to Tamoxifen, a breast cancer hormone therapy, could prevent 434 deaths each year among women with breast cancer, and save up to £30 million (equivalent of nearly $50 million) in healthcare costs.[1]

"Research indicates as many as 41% of women choose to discontinue their breast cancer treatment," confirms John Weinman, Professor of Psychology as applied to Medicine at King's College London, who reviewed this new report. "While this may seem surprising, it's important to consider why they make this decision."

"Research shows there are certain factors that contribute to non-adherence in breast cancer, including treatment side effects, an individual's personal beliefs about their treatment and condition, and the quality of their healthcare consultations."

Professor Weinman explains that there are ways to help women overcome these challenges.

"The evidence clearly shows that for a support intervention to improve adherence, it must be personalized. As reasons for non-adherence differ between individuals, interventions should be tailored according to a person's unique needs and preferences."

As described in the report, this approach is currently being investigated by other scientists in breast cancer. In a major project funded by the Breast Cancer Research Foundation, Professor Annette Stanton from the University of California and her colleagues Professor Keith Petrie (University of Auckland) and Dr. Ann Partridge (Harvard Medical School) recruited over 1,000 women who had taken hormone therapy for breast cancer within the previous twelve months.  Their study concluded that different women have different support needs, and these must be addressed to have a significant impact on adherence rates. "Some women may truly benefit from information and education about the importance of medication in terms of survival benefit. Some women may need information on how to deal with the side effects," says Professor Stanton.

Professor Weinman concludes, "Just as treatments for breast cancer are becoming increasingly personalized, so too should interventions designed to support patients taking them."

To download the breast cancer Adherence Research Summarized™ report, click here.

About Atlantis Healthcare
Established in 1993, Atlantis Healthcare creates and executes tailored patient support programs and personalized interventions to address treatment adherence across a wide range of chronic and acute diseases, worldwide.  Led by one of the world's largest health psychology teams, our patient-centric approach is designed to improve health outcomes and deliver optimal value for all healthcare stakeholders. 

Atlantishealthcare.com/US

[1] McCowan C, Wang S, Thompson AM, et al, The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study, Br J Cancer. 2013 Sep 3;109(5):1172-80. doi: 10.1038/bjc.2013.464. Epub 2013 Aug 15.


'/>"/>
SOURCE Atlantis Healthcare
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
5. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
6. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
7. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
8. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
9. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
10. Chindex International, Inc. to Report First Quarter 2012 Financial Results
11. Pharma IQs Solubility Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):